Overview

Lacosamide in Migraine Prevention

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Our aim is to study the effect of lacosamide as a preventive treatment of migraine by assessing the change in the disease duration, attack frequency, and duration, pain intensity assessed by visual analogic scale, and The Migraine Disability Assessment Test after 90 days of regular use of 50 mg lacosamide twice daily. in patients diagnosed to have migraine based upon the International Classification of Headache Disorders (ICHD) 3rd edition.
Phase:
Phase 3
Details
Lead Sponsor:
Kafrelsheikh University
Treatments:
Lacosamide